| Drug General Information |
| Drug ID |
D0Y6HA
|
| Former ID |
DIB007840
|
| Drug Name |
CYC-103
|
| Synonyms |
CYC-103; Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Terminated |
[1]
|
|---|
| Company |
Cyclacel Pharmaceuticals Inc
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@<br />@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1nc[nH]c1)N<br />)C)CCCCN)CCCNC(=N)N)CCCNC(=N)N)CC(C)C)[C@H](CC)C)(C(=O)<br />O)[C@H](c1ccccc1)O
|
| Target and Pathway |
| Target(s) |
Cell division protein kinase 6 |
Target Info |
Inhibitor |
[2]
|
|---|
| Cell division protein kinase 4 |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
Cell cycle
|
|
p53 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Hepatitis B
|
|
Measles
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Glioma
|
|
Melanoma
|
|
Chronic myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancerhsa04110:Cell cycle
|
|
Tight junction
|
|
T cell receptor signaling pathway
|
|
HTLV-I infection
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
Pathway Interaction Database
|
p73 transcription factor network
|
|
Coregulation of Androgen receptor activity
|
|
C-MYB transcription factor network
|
|
IL2 signaling events mediated by STAT5
|
|
Regulation of retinoblastoma proteinsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Validated targets of C-MYC transcriptional activation
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Oxidative Stress Induced Senescence
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
Oncogene Induced Senescence
|
|
Cyclin D associated events in G1R-HSA-2559580:Oxidative Stress Induced Senescence
|
|
RMTs methylate histone arginines
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Ubiquitin-dependent degradation of Cyclin D1
|
|
Cyclin D associated events in G1
|
|
Meiotic recombination
|
|
WikiPathways
|
DNA Damage Response
|
|
G1 to S cell cycle control
|
|
Wnt Signaling Pathway Netpath
|
|
Retinoblastoma (RB) in Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
Metastatic brain tumor
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Mitotic G1-G1/S phases
|
|
Cell Cycle
|
|
miRNAs involved in DNA damage response
|
|
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
|
|
Ovarian Infertility Genes
|
|
PPAR Alpha Pathway
|
|
Bladder Cancer
|
|
S Phase
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Meiotic Recombination
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015455) |
|---|
| REF 2 | WO patent application no. 2007,0898,78, Sutures and anti-scarring agents. |
|---|
| REF 3 | Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. |
|---|
